Valuation: Genelux Corporation

Market Cap 131M 115M 107M 98.47M 185M 12.52B 188M 1.27B 497M 6.21B 492M 481M 21.45B P/E 2026 *
-3.6x
P/E 2027 * -3.94x
Enterprise Value 131M 115M 107M 98.47M 185M 12.52B 188M 1.27B 497M 6.21B 492M 481M 21.45B EV / Sales 2026 *
-
EV / Sales 2027 * 10.8x
Free-Float
86.05%
Yield 2026 *
-
Yield 2027 * -
1 day-0.85%
1 week+1.04%
Current month-2.99%
1 month+0.69%
3 months+15.42%
6 months+5.80%
Current year-33.03%
1 week 2.85
Extreme 2.85
3
1 month 2.78
Extreme 2.775
3.18
Current year 2.29
Extreme 2.29
4.99
1 year 2.29
Extreme 2.29
8.54
3 years 1.6
Extreme 1.6
30.44
5 years 1.6
Extreme 1.6
40.98
10 years 1.6
Extreme 1.6
40.98
Manager TitleAgeSince
Chief Executive Officer 67 28/05/2014
Director of Finance/CFO 42 30/01/2025
Chief Tech/Sci/R&D Officer 52 02/01/2026
Director TitleAgeSince
Director/Board Member 68 01/09/2002
Chairman 73 01/01/2014
Chairman 67 01/04/2023
Date Insider Type Main position Quantity % Market Cap.
7/1/26 A Sell

Director

-12,000 0.0268%
6/16/26 A Free

Chief Financial Officer

278,906 0.6220%
6/16/26 A Free

Director

59,975 0.1338%
Change 5-day change 1-year change 3-year change Capi.($)
-0.85%+1.04%-13.86%-86.21% 131M
-2.25%+1.55%+50.84%+70.04% 56.19B
-1.32%-0.97%+38.41%+77.52% 54.83B
+1.32%-0.13%-18.25%-14.16% 23.04B
+0.32%-3.36%+3.16%+391.66% 22.7B
-0.21%+0.84%+22.48%-7.92% 20.23B
0.00%+3.00%+27.41%-29.52% 17.83B
-0.97%+0.89%+37.28%+539.62% 15.65B
-6.69%-5.11%+166.00%+304.89% 15.24B
+0.28%+0.53%+27.09%+184.21% 14.03B
Average -1.04%+0.05%+34.06%+143.01% 23.99B
Weighted average by Cap. -1.16%+0.42%+37.72%+132.28%

Financials

2026 *2027 *
Net sales - 12.18M 10.69M 9.96M 9.16M 17.16M 1.16B 17.46M 118M 46.23M 577M 45.73M 44.75M 1.99B
Net income -37.1M -32.56M -30.32M -27.89M -52.27M -3.54B -53.17M -360M -141M -1.76B -139M -136M -6.07B -37.87M -33.23M -30.95M -28.46M -53.36M -3.62B -54.27M -367M -144M -1.79B -142M -139M -6.2B
Net Debt - -
Logo Genelux Corporation
Genelux Corporation is a late clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.
Employees
26
Date Price Change Volume
28/07/26 $2.925 -0.85% 126,723
27/07/26 $2.950 +2.08% 66,498
24/07/26 $2.890 -2.36% 153,708
23/07/26 $2.960 0.00% 141,379
22/07/26 $2.960 +2.42% 108,167
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.950USD
Average target price
17.50USD
Spread / Average Target
+493.22%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GNLX Stock